SecBot SecBot
8-K ·Filed Aug 5, 2026

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001100682-26-000115
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The Q2 beat and guidance raise, especially the first organic revenue growth since 2023 and the highest DSA book-to-bill in nearly four years, suggest a cyclical recovery in drug development outsourcing. The company's Investor Day on September 24, 2026 will provide further strategic detail. Traders should watch for continued order momentum and margin expansion as the divested businesses are behind the company.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$260.72
T+0 close · Aug 5, 2026 · via day close
Latest settled
+44.25%
T+60 · $376.10
Vs SPY
+44.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $260.72entry
  2. T+1 · 3mo ago +1.84%α +2.00% · $265.51
  3. T+5 · 3mo ago +9.07%α +8.72% · $284.37
  4. T+20 · 3mo ago +11.91%α +12.51% · $291.76
  5. T+60 · 19d ago +44.25%α +44.31% · $376.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Charles River Laboratories reported Q2 2026 revenue of $1.00B (down 2.7% reported / +0.1% organic YoY) and non-GAAP EPS of $3.02, beating consensus estimates of $2.73 by 10.6%. The company raised its full-year organic revenue guidance to 0.0%-1.0% (from -1.5% to -0.5%) and its non-GAAP EPS guidance to $11.15-$11.45, driven by improving demand in DSA and better-than-expected Manufacturing performance. This marks the first quarter of organic revenue growth since Q3 2023 and signals a potential inflection in underlying demand trends.

Key Financial Metrics

EPS
$3.02
est $2.73 · +10.6%
Revenue
$1.0B
est $977.2M · +2.8% · -2.7% YoY
Rating
strong beat
Guidance
0.0% to 1.0% organic growth
raised

Key Facts

  • Q2 2026 total revenue $1.00B vs consensus $977.2M; organic revenue grew 0.1% YoY (first positive since Q3 2023)
  • Non-GAAP EPS $3.02 beats consensus of $2.73 by 10.6% (down 3.2% from $3.12 a year ago)
  • Raised 2026 organic revenue guidance to 0.0%-1.0% from (1.5%)-(0.5%) and non-GAAP EPS to $11.15-$11.45 from $10.80-$11.30
  • GAAP net loss of $(0.03)/share driven by $63.7M loss on CDMO & Cell Solutions divestiture completed in May 2026
  • Non-GAAP operating margin 20.5% improved 420 bps sequentially from Q1 2026 (16.3%) but down 160 bps YoY
  • Repurchased $100M of common stock in Q2 at avg price $174; $700M remaining under $1.0B authorization
  • DSA segment achieved highest net book-to-bill in nearly four years, indicating strengthening demand
  • Completed divestitures of CDMO, Cell Solutions, and certain European Discovery Services sites in May 2026

Financial Impact

Non-GAAP EPS beat of $0.29 vs consensus ($3.02 vs $2.73) and full-year guidance raised by $0.25 at midpoint; revenue beat of $27M vs consensus

revenueepsguidanceoperating margin

Risk Factors

  • RMS organic revenue declined 1.4% YoY, and non-GAAP operating margin contracted in all three segments
  • Non-GAAP EPS guidance increase partly offset by higher tax rate and deferred comp investment gains that may not recur
  • Guidance assumes successful execution of restructuring and efficiency initiatives; any delays could pressure margins
  • GAAP earnings remain deeply negative due to divestiture-related charges; underlying cash flow metrics warrant monitoring

Market Snapshot

Exchange
NYSE
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
68% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001100682-26-000115
Document: crl-20260805.htm0001100682-26-000115
Document: 0001100682-26-000115-index-headers.html0001100682-26-000115
Document: 0001100682-26-000115-index.html0001100682-26-000115
Document: 0001100682-26-000115.txt0001100682-26-000115
8-K Data (Synthetic)0001100682-26-000115

US Market Status

Market Closed · Opens in 8h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026